Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

About this update from Aytu Biopharma, Inc.

DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023 , after the market close on Wednesday, February 14, 2024 . The Company has scheduled a conference call and webcast that same day, Wednesday, February 14, 2024 , at 4:30 p.m. Eastern time , to review the results followed by a question and answer section. Conference Call Details Date and Time : Wednesday, February 14, 2024 , at 4:30 p.m. Eastern time Call-in Information : Interested parties can access the conference call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers and using the participant access code 566278. Webcast Information: The webcast will be accessible live and archived at the following link, https://www.webcaster4.com/Webcast/Page/2142/49729 and on the Company's website, within the Investors section under Events & Presentations, at aytubio.com , and may be discontinued at any time. Replay: A teleconference replay of the call will be available until February 28, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 49729. About Aytu BioPharma, Inc. Aytu BioPharma is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com . Contacts for Investors: Mark Oki , Chief Financial Officer Aytu BioPharma, Inc. [email protected] Robert Blum or Roger Weiss Lytham Partners [email protected] SOURCE: Aytu BioPharma, Inc. View the original press release on accesswire.com

View stock analysis, news, and events for Aytu Biopharma, Inc.